Special Situations & Edge Cases in Cold Agglutinin Disease

Prev
 1 / 22 
Next
Prev
 1 / 22 
Next

Learning objectives

After completing this quiz, the learner should be able to:

  • distinguish primary CAD from transient or incidental cold agglutinin states
  • recognize when symptoms or anemia are discordant with laboratory severity
  • identify scenarios where standard CAD frameworks must be modified
  • apply mechanism-based reasoning in perioperative, infectious, or mixed presentations
  • avoid overtreatment driven by labels rather than trajectory and impact
  • recognize when partial control represents appropriate success

Which feature most strongly distinguishes post-infectious cold agglutinin hemolysis from primary CAD?

a
Presence of IgM antibodies
IgM may be present in both.
b
Complement activation
Complement activation can occur transiently after infection.
c
Association with an underlying clonal B-cell disorder
Post-infectious cold agglutinins are typically polyclonal and lack a clonal marrow driver, unlike primary CAD.
d
Cold-induced symptoms
Cold symptoms can occur in either setting.

Which management approach is most appropriate for an asymptomatic patient with incidentally detected cold agglutinins and no hemolysis?

a
Clone-directed therapy
Treating a marker as disease risks overtreatment.
b
Complement inhibition
Treating a marker as disease risks overtreatment.
c
Immediate transfusion planning
Treating a marker as disease risks overtreatment.
d
Observation with serial monitoring
Cold agglutinin presence alone does not equal CAD.

A patient with CAD reports severe fatigue and acrocyanosis but has hemoglobin 11.5 g/dL. What best explains this discordance?

a
Laboratory error
Labs may be accurate yet incomplete.
b
Psychosomatic symptoms
Symptoms are biologically real.
c
IgM-mediated agglutination, microvascular dysfunction, and complement effects D. Compensated intravascular hemolysis
Circulatory and complement-mediated effects can dominate even with modest anemia.
d
Compensated intravascular hemolysis
Intravascular hemolysis is usually limited in CAD.

Which statement best reflects expert judgment in a patient with severe anemia but minimal symptoms?

a
Disease-directed therapy is mandatory
Numeric severity alone does not dictate urgency.
b
Transfusion should always be avoided
Transfusion may be appropriate depending on reserve and trajectory.
c
Urgency should be guided by trajectory, comorbidities, and physiologic reserve
Context and trend matter more than the number.
d
Symptoms should determine treatment regardless of hemoglobin
Symptoms matter, but so do reserve and risk.

An acute hemolytic flare occurs after surgery in a previously stable CAD patient. What is the most appropriate interpretation?

a
The long-term strategy has failed
A flare is not automatically strategic failure.
b
This represents expected disease behavior under physiologic stress
Stressors (infection, surgery, hypothermia) often precipitate transient exacerbations.
c
Clone-directed therapy must be escalated permanently
Symptoms and Acute escalation does not necessarily imply permanent strategy change.
d
It proves the diagnosis was incorrect
Diagnosis is not invalidated by variability.

Which perioperative principle is most important in CAD?

a
Routine preoperative transfusion
Transfusion planning is individualized.
b
Avoidance of anesthesia
Most procedures are feasible with planning.
c
Proactive temperature management and team coordination
Preventing hypothermia is the most actionable, preventable risk.
d
Universal perioperative complement inhibition
Complement inhibition may be considered selectively, not routinely.

Which finding most strongly suggests a pre-analytical cold artifact rather than true macrocytosis?

a
Elevated LDH
Reflect hemolysis, not artifact.
b
Low haptoglobin
Reflect hemolysis, not artifact.
c
Spuriously elevated MCV and MCHC that normalize with warming
Classic cold agglutination artifact.
d
Positive DAT
DAT reflects immune coating, not sample temperature handling.

A patient meets criteria for Waldenström macroglobulinemia and also has cold agglutinin hemolysis. Which principle most often guides therapy selection?

a
Lymphoma biology and malignancy indications may drive therapy, with CAD managed as a consequence
Treat the disease that is driving overall risk, while managing hemolysis appropriately.
b
CAD severity always determines treatment choice
Malignancy indications can supersede hemolysis considerations.
c
Complement inhibition should replace malignancy-directed treatment
Complement therapy does not treat tumor burden.
d
Clone-directed therapy is contraindicated in CAD with lymphoma
Not contraindicated, but strategy is contextual.

Which scenario should prompt mechanism reassessment rather than reflex escalation of the existing plan?

a
Persistent cold intolerance
Symptoms alone do not mandate escalation.
b
Stable anemia over time
Stability may represent acceptable control.
c
A patient prefers conservative pacing
Preference is not pathology.
d
Lymphoma responds but hemolysis persists (or vice versa)
Discordance is a signal to re-check mechanism (mixed AIHA, ongoing complement drive, alternate trigger).

A patient’s DAT is positive for both IgG and C3 with evidence of hemolysis at warm and cold temperatures. Which interpretation is most appropriate?

a
Typical primary CAD
Pure CAD is typically C3-predominant with weak/absent IgG.
b
Warm AIHA with incidental cold agglutinins
Possible, but the pattern described supports mixed disease.
c
Mixed AIHA requiring integrated management targeting the dominant process over time
Mixed AIHA is a mechanism problem, not a label problem.
d
The warm component should be ignored
Ignoring one mechanism leads to persistent hemolysis.

A frail 85-year-old with CAD and multiple comorbidities has Hb 8.5 g/dL with moderate fatigue. Which factor most strongly influences treatment intensity?

a
Hemoglobin level alone
: Numbers matter, but context matters more.
b
Cold agglutinin titer
Titer often correlates poorly with impact.
c
Functional status and treatment tolerance
Frailty and tolerance reshape the risk–benefit balance.
d
Bone marrow clone size
Clone burden correlates poorly with phenotype.

A pregnant patient with known CAD develops worsening anemia. Which consideration is most important when selecting therapy?

a
Whether hemoglobin is below 10 g/dL
Thresholds do not substitute for risk assessment.
b
Fetal safety and the limits of available evidence
Evidence is limited and safety data constrain options.
c
Whether cold agglutinin titer is rising
May inform mechanism but do not drive safety.
d
Whether the DAT is strongly positive
May inform mechanism but do not drive safety.

Which approach best fits management of post-infectious cold agglutinin hemolysis in most cases?

a
Observation and supportive care, reserving escalation for severe or persistent hemolysis
Most cases are self-limited.
b
Clone-directed therapy
Inappropriate without a clonal driver.
c
Complement inhibition as default
Rarely required.
d
Immediate long-term CAD therapy to prevent recurrence
Overtreatment.

Sort each scenario by its primary posture

Mixed AIHA features (IgG + C3 with ongoing hemolysis)
Refractory disease despite appropriate therapy
Severe anemia with preserved function and stable trajectory
Post-infectious cold agglutinins with resolving anemia
Incidental cold agglutinins without hemolysis
Discordant lymphoma response and persistent hemolysis (or vice versa)
Acute perioperative hemolysis flare
Observation / supportive care / monitoring
Active reassessment / adjustment

Match each scenario to its dominant guiding principle:

Discordant lymphoma and hemolysis responses
Post-infectious cold agglutinins
Perioperative setting
Anticipate hypothermia and physiologic stress, coordinate early
Re-check mechanism before escalation
Avoid misclassification and overtreatment
Correct! Sorry, Incorrect.

Closing Note

Edge cases are not failures of the CAD framework.
They are where it proves its value.

When rules bend, expert care returns to first principles:
mechanism, trajectory, reserve, and impact.

Prev
 1 / 22 
Next